Quantcast

Latest PARP inhibitor Stories

2013-02-04 10:19:38

Double-strand breaks in DNA happen every time a cell divides and replicates. Depending on the type of cell, that can be pretty often. Many proteins are involved in everyday DNA repair, but if they are mutated, the repair system breaks down and cancer can occur. Cells have two complicated ways to repair these breaks, which can affect the stability of the entire genome. Roger A. Greenberg, M.D., Ph.D., associate investigator, Abramson Family Cancer Research Institute and associate professor...

2013-01-22 10:40:39

Cancer cells are resourceful survivors with plenty of tricks for staying alive. Researchers have uncovered one of these stratagems, showing how cells lacking the tumor suppressor BRCA1 can resume one form of DNA repair, sparing themselves from stagnation or death. The study appears in the January 21st issue of The Journal of Cell Biology. The BRCA1 protein helps to mend double-strand DNA breaks by promoting homologous recombination. Without it, cells can amass broken, jumbled, and fused...

2012-11-13 12:15:34

-PI3-kinase inhibitors sensitized tumors to PARP inhibitors. -Combination significantly prolonged progression-free survival in mouse model. The simultaneous inhibition of two separate and seemingly unrelated pathways could potentially provide an effective treatment for women with triple-negative breast cancer, according to results of two studies published in the November issue of Cancer Discovery, a journal of the American Association for Cancer Research. Triple-negative breast cancers...

2012-05-11 10:30:15

Researchers at Jefferson's Kimmel Cancer Center capture a major chemotherapeutic target in complex with DNA damage, revealing novel targets for new PARP-1 inhibitors A new study published in Science May 11 is shedding light on the molecular details of PARP-1, a DNA damage-detecting enzyme that when inhibited has been shown to be effective in fighting cancer and other diseases. The investigation led by John M. Pascal, Ph.D., an assistant professor in the Department of Biochemistry and...

2012-02-21 12:32:20

A team of researchers at Karolinska Institutet has generated a map over the effects of small drug-like molecules on PARP1 and other similar proteins in the body. This map may explain the mechanism behind putative side effects of the so-called PARP inhibitors, and can play an important role in the development of novel tailor-made cancer drugs. The study is presented in the journal Nature Biotechnology, and will hopefully contribute to new cancer therapies with fewer detrimental side effects....

2011-12-12 23:35:09

Looking for ways to halt the uncontrolled growth of cancer cells, scientists at Johns Hopkins have found that a new class of drugs, called PARP inhibitors, may block the ability of pre-leukemic cells to repair broken bits of their own DNA, causing these cells to self-destruct. Results of their experiments, expected to be presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, Dec. 12, have already prompted clinical trials of the drugs in patients with...

2011-07-14 15:42:00

NOVATO, Calif., July 14, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies. A Phase 1/2 trial for BMN 673 for the treatment of patients with solid tumors was initiated in January 2011 and is ongoing. "We are excited to be at the forefront of studying the potential benefit of PARP inhibitors in...

2011-06-30 13:41:10

Researchers at Dana-Farber Cancer Institute have demonstrated a molecular strategy they say could make a much larger variety of tumors treatable with PARP inhibitors, a promising new class of cancer drugs. Currently, the role of PARP inhibitors has mainly been restricted to cancers whose cells lack functioning versions of the damage-repair proteins BRCA1 or BRCA2 -- chiefly certain breast and ovarian cancers. In a paper published online by Nature Medicine, Geoffrey Shapiro, MD, and colleagues...

2011-06-02 14:17:00

BOULDER, Colo., June 2, 2011 /PRNewswire/ -- Clovis Oncology, Inc. announced today an agreement with Pfizer Inc. (NYSE: PFE) for the development and commercialization of Pfizer's oral and IV Poly (ADP-ribose) polymerase (PARP) inhibitor, PF-01367338, currently in Phase 1/2 development for solid tumors. PF-01367338 is a novel, orally active, small molecule inhibitor of PARP and will be developed by Clovis as both a monotherapy and in combination with chemotherapeutic agents for the...

2011-04-25 14:54:44

15 percent of colorectal cancers have mutation that responds to PARP inhibitors A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds. Working in cell lines from colorectal cancer patients, researchers found that a new class of drugs called PARP inhibitors worked against tumors with mutations...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related